Deutsche Bank AG Has $1.40 Million Stock Position in REGENXBIO Inc. $RGNX

Deutsche Bank AG cut its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 2.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 195,202 shares of the biotechnology company’s stock after selling 5,173 shares during the quarter. Deutsche Bank AG owned approximately 0.39% of REGENXBIO worth $1,396,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of RGNX. FNY Investment Advisers LLC acquired a new stake in REGENXBIO in the first quarter valued at about $35,000. Pallas Capital Advisors LLC acquired a new stake in REGENXBIO in the first quarter valued at about $74,000. Laurion Capital Management LP acquired a new stake in REGENXBIO in the fourth quarter valued at about $79,000. Tower Research Capital LLC TRC boosted its stake in REGENXBIO by 442.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 10,714 shares in the last quarter. Finally, Corton Capital Inc. acquired a new stake in REGENXBIO in the fourth quarter valued at about $103,000. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Stock Up 11.1%

Shares of NASDAQ:RGNX opened at $9.01 on Friday. The stock has a market cap of $455.10 million, a price-to-earnings ratio of -2.62 and a beta of 1.11. REGENXBIO Inc. has a 12-month low of $5.03 and a 12-month high of $13.48. The business’s 50 day moving average is $8.52 and its 200 day moving average is $8.07.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The company had revenue of $21.36 million for the quarter, compared to analysts’ expectations of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. As a group, equities research analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Wall Street Zen lowered REGENXBIO from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 9th. Barclays cut their price target on REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Royal Bank Of Canada cut their price target on REGENXBIO from $21.00 to $17.00 and set an “outperform” rating on the stock in a research note on Friday, August 8th. HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of REGENXBIO in a research note on Tuesday, August 19th. Finally, Chardan Capital reissued a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research note on Friday, August 8th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus price target of $28.38.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.